HALO vs XLV
Halozyme Therapeutics Inc (HALO) versus Health Care Select Sector SPDR® Fund (XLV) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Health Care Select Sector SPDR® Fund (XLV) common stock listed on US.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
XLV does not have a complete income-statement cache yet.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. XLV currently screens at market cap $0.
Not investment advice. Open the HALO and XLV stock pages for the full models.
Not investment advice.